The FIRIS study previously demonstrated non-inferiority of IRIS ( irinotecan plus S-1 ) to FOLFIRI ( 5-fluorouracil/leucovorin with irinotecan ) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer ( mCRC ) as the primary endpoint .